Business Wire

GENFIT and LabCorp Sign a Licensing Agreement to Expand Access to an Innovative Diagnostic Assay for Non-Alcoholic Steatohepatitis (NASH)

Multi-Biomarker Test Will Provide the Clinical Research Community with a Non-Invasive Tool to Identify and Monitor Patients with NASH and Significant Fibrosis LILLE, France & CAMBRIDGE, Mass. & ...
Nasdaq

GENFIT and LabCorp Sign Exclusive Agreement to Commercialize a Novel Diagnostic Test for Liver Disease

Lille, France; Cambridge, MA; [AND Burlington, N.C.,] September 28, 2020 GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with ...
Business Wire

LabCorp and Envigo Sign Innovative Agreement to Expand Covance’s Nonclinical Drug Development Capabilities and Create an Independent Research Models Provider

LabCorp will purchase Envigo’s nonclinical contract research services business, expanding the global reach and capabilities of Covance’s nonclinical drug development business Envigo’s research models ...
Business Insider

GENFIT and LabCorp Sign Exclusive Agreement to Commercialize a Novel Diagnostic Test for Liver Disease

Innovative multi-biomarker blood test based on GENFIT’S NIS4™ technology is specifically designed to identify patients with at-risk non-alcoholic steatohepatitis (NASH) LabCorp to commercialize the ...